MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its position in MacroGenics, Inc. (NASDAQ:MGNXFree Report) by 32.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,204 shares of the biopharmaceutical company’s stock after purchasing an additional 48,118 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.31% of MacroGenics worth $905,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of MGNX. Swiss National Bank increased its stake in shares of MacroGenics by 7.6% in the first quarter. Swiss National Bank now owns 115,800 shares of the biopharmaceutical company’s stock valued at $1,020,000 after buying an additional 8,200 shares during the period. JPMorgan Chase & Co. boosted its holdings in MacroGenics by 195.5% during the first quarter. JPMorgan Chase & Co. now owns 283,760 shares of the biopharmaceutical company’s stock worth $2,500,000 after buying an additional 187,724 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in MacroGenics during the first quarter worth about $329,000. MetLife Investment Management LLC lifted its holdings in shares of MacroGenics by 58.3% in the first quarter. MetLife Investment Management LLC now owns 33,326 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 12,267 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of MacroGenics by 2.2% in the first quarter. Vanguard Group Inc. now owns 4,032,239 shares of the biopharmaceutical company’s stock valued at $35,524,000 after buying an additional 86,061 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MGNX has been the topic of several research analyst reports. JMP Securities raised their price objective on shares of MacroGenics from $10.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Wednesday, January 24th. Citigroup upgraded shares of MacroGenics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.00 to $13.00 in a report on Wednesday, December 20th. HC Wainwright reduced their price objective on shares of MacroGenics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, November 13th. Guggenheim raised shares of MacroGenics from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Tuesday, November 7th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $17.00 price objective on shares of MacroGenics in a research report on Monday, November 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, MacroGenics has a consensus rating of “Moderate Buy” and an average price target of $13.67.

Check Out Our Latest Research Report on MacroGenics

MacroGenics Price Performance

NASDAQ:MGNX opened at $17.92 on Tuesday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 22.40 and a beta of 2.16. MacroGenics, Inc. has a 1-year low of $4.29 and a 1-year high of $18.85. The firm’s fifty day moving average price is $11.47 and its 200 day moving average price is $7.60.

Insider Activity

In other MacroGenics news, SVP Ezio Bonvini sold 13,316 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $12.00, for a total value of $159,792.00. Following the completion of the transaction, the senior vice president now owns 87,984 shares in the company, valued at approximately $1,055,808. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 45,512 shares of company stock valued at $549,842 in the last 90 days. 10.00% of the stock is currently owned by insiders.

MacroGenics Profile

(Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Further Reading

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNXFree Report).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.